Related Experiment Video
Updated: Jul 7, 2026

Antimicrobial Characterization of Advanced Materials for Bioengineering Applications
Published on: August 4, 2018
New antimicrobial agents for the treatment of Gram-positive bacterial infections
1Department of Internal Medicine, Medical Faculty, Hacettepe Univrsity, Ankara, Turkey. duyguyaks@yahoo.com
Abstract:
Since the 1970s, resistance to antimicrobial agents has become an escalating problem. In the last 25 years, treatment of infections caused by Gram-positive bacteria has been more problematical than ever, with infections being caused by multidrug-resistant organisms, particularly methicillin-resistant staphylococci, penicillin- and erythromycin-resistant pneumococci, and vancomycin-resistant enterococci. There is a continuing effort in the pharmaceutical industry to develop new antimicrobial agents for the treatment of resistant infections. Linezolid, quinupristin-dalfopristin, daptomycin, tigecyline, new glycopeptides and ceftobiprole are the main agents recently introduced or under clinical development. This review summarises their major properties, the results of recent studies with these agents, and future treatment possibilities.
Insights
Antimicrobial resistance is a growing global health threat, especially for Gram-positive bacterial infections. New drugs like linezolid and daptomycin offer hope for treating resistant infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Antimicrobial resistance has escalated since the 1970s, complicating treatment of Gram-positive bacterial infections.
- Multidrug-resistant organisms such as MRSA, resistant pneumococci, and VRE pose significant clinical challenges.
- The pharmaceutical industry is actively developing novel antimicrobial agents to combat these resistant infections.
Purpose of the Study:
- To review recently introduced and clinically developing antimicrobial agents.
- To summarize the properties and recent study results of these new agents.
- To discuss future treatment possibilities for resistant infections.
Main Methods:
- Literature review of recent studies on new antimicrobial agents.
- Analysis of properties and clinical data for agents like linezolid, quinupristin-dalfopristin, daptomycin, tigecycline, new glycopeptides, and ceftobiprole.
Main Results:
- Several new agents including linezolid, quinupristin-dalfopristin, daptomycin, tigecycline, new glycopeptides, and ceftobiprole are available or in development.
- These agents exhibit diverse mechanisms of action and spectrums of activity against resistant Gram-positive pathogens.
- Recent studies demonstrate varying efficacy and safety profiles for these novel therapeutics.
Conclusions:
- New antimicrobial agents are crucial for managing infections caused by multidrug-resistant Gram-positive bacteria.
- Continued research and development are essential to address the evolving challenge of antimicrobial resistance.
- These emerging therapies hold promise for improving treatment outcomes in the future.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Antimicrobial Effectiveness
Inhibitors of Bacterial Protein Synthesis
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Clinical Significance of Antibiotic Resistance
Chemical Agents for Microbial Control

